Private Equity
Latest news, explainers and analysis on Private Equity. Tracking 6 stories on Arth Vani.
Connected in the graph
Latest on Private Equity
Indian Biotech Sector Booms as Startup Count Hits 2,400; PE Investments Double
India's pharmaceutical and biotech landscape is witnessing a massive shift with private equity investments doubling to $731 million. A new report highlights that the number of biotech startups has surged to 2,400, signaling a robust pipeline for new drug development.
SpaceX Shares: What Indian Investors Should Know About Private Market Holdings
While SpaceX is a prominent global company, its shares are not publicly traded on stock exchanges. Indian investors holding private SpaceX shares need to understand the nuances of such investments, including liquidity challenges and valuation complexities.
Wealthy Indians Eye Direct Alternative Investments, Bypassing Traditional Funds
High-net-worth individuals in India are increasingly seeking direct access to alternative investments like private equity and real estate, moving away from traditional fund structures. This shift is driven by a desire for greater control, potentially higher returns, and lower fees, as they look to diversify beyond conventional stocks and bonds.
Sebi Eases Exit Rules for AIFs: Funds Can Now Retain Assets Beyond Expiry
Market regulator Sebi has introduced new guidelines allowing Alternative Investment Funds (AIFs) to manage and retain liquidation proceeds even after their formal tenure ends. This move aims to prevent distressed sales and ensure better returns for high-net-worth investors.
Carlyle Prepares to Launch Healthcare Services IPO in India
Global private equity firm Carlyle is eyeing a public listing for its healthcare revenue cycle management platform. The company, formed by merging Knack RCM and EqualizeRCM, is currently in the process of selecting investment banks to manage the debut.
Kotak Mutual Fund Invests ₹612 Crore in Emcure Pharma; PE Firm BC Investments Exits
Private equity firm BC Investments IV has sold its stake in Emcure Pharmaceuticals to Kotak Mutual Fund for ₹612 crore. This major transaction highlights growing institutional confidence in Emcure's growth potential across key medical segments.
Some listings may be sponsored and Arth Vani may earn a referral fee. All information is for educational purposes only — verify terms and suitability with the provider before acting. Not financial advice.